Patents by Inventor Laura J. Jelinek

Laura J. Jelinek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mammalian secretory peptide - 9
    Publication number: 20040110927
    Abstract: Novel mammalian secretory polypeptides, polynucleotides encoding the polypeptides (called Zsig9), and related compositions and methods including antibodies and anti-idiotypic antibodies. Overexpression of these proteins is indicative of the presence of cancer. Antibodies and anti-sense nucleotides can be used therapeutically to treat the disease. Furthermore, antibodies to Zsig9 and nucleotide primers and probes can be used to diagnose the presence of tumors.
    Type: Application
    Filed: November 19, 2003
    Publication date: June 10, 2004
    Inventors: Paul O. Sheppard, Laura J. Jelinek
  • Islet cell antigen 1851
    Patent number: 6627735
    Abstract: A mammalian islet cell antigen polypeptide involved in the development of insulin-dependent diabetes mellitus (IDDM) is disclosed. This islet cell antigen polypeptide, 1851, was found to contain regions of homology to the protein tyrosine phosphatase family. Methods for diagnosis and treatment, including use in immunoprecipitation assays and the induction of immune tolerance using the recombinant mammalian polypeptides and antibodies specific to mammalian islet cell antigen 1851 polypeptides are presented.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: September 30, 2003
    Assignee: ZymoGenetics, Inc.
    Inventors: Wayne Kindsvogel, Laura J. Jelinek, Paul O. Sheppard, William A. Hagopian, James M. LaGasse
  • Mammalian secretory peptide - 9
    Publication number: 20030171542
    Abstract: Novel mammalian secretory polypeptides, polynucleotides encoding the polypeptides (called Zsig9), and related compositions and methods including antibodies and anti-idiotypic antibodies. Overexpression of these proteins is indicative of the presence of cancer. Antibodies and anti-sense nucleotides can be used therapeutically to treat the disease. Furthermore, antibodies to Zsig9 and nucleotide primers and probes can be used to diagnose the presence of tumors.
    Type: Application
    Filed: October 19, 2001
    Publication date: September 11, 2003
    Applicant: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Laura J. Jelinek
  • Islet cell antigen 1851
    Publication number: 20030166067
    Abstract: A mammalian islet cell antigen polypeptide involved in the development of insulin-dependent diabetes mellitus (IDDM) is disclosed. This islet cell antigen polypeptide, 1851, was found to contain regions of homology to the protein tyrosine phosphatase family. Methods for diagnosis and treatment, including use in immunoprecipitation assays and the induction of immune tolerance using the recombinant mammalian polypeptides and antibodies specific to mammalian islet cell antigen 1851 polypeptides are presented.
    Type: Application
    Filed: April 16, 2002
    Publication date: September 4, 2003
    Applicant: ZymoGenetics, Inc.
    Inventors: Wayne Kindsvogel, Laura J. Jelinek, Paul O. Sheppard, William A. Hagopian, James M. LaGasse
  • Mammalian neuro-growth factor like protein
    Publication number: 20030166907
    Abstract: Novel mammalian Zneu1 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods including antibodies and anti-idiotypic antibodies.
    Type: Application
    Filed: May 10, 2001
    Publication date: September 4, 2003
    Applicant: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Laura J. Jelinek
  • Human gene marker for metabolic disease
    Publication number: 20020164701
    Abstract: The present invention provides methods for identifying abnormalities in human chromosome 11 that are linked to defects in glucose metabolism. The present invention also provides methods for identifying polymorphisms in a new human gene that resides on chromosome 11q23-q24, a locus linked with a heritable form of diabetes.
    Type: Application
    Filed: October 25, 2001
    Publication date: November 7, 2002
    Inventors: Paul O. Sheppard, Laura J. Jelinek, Theodore E. Whitmore
  • Islet cell antigen 1851
    Publication number: 20020102616
    Abstract: A mammalian islet cell antigen polypeptide involved in the development of insulin-dependent diabetes mellitus (IDDM) is disclosed. This islet cell antigen polypeptide, 1851, was found to contain regions of homology to the protein tyrosine phosphatase family. Methods for diagnosis and treatment, including use in immunoprecipitation assays and the induction of immune tolerance using the recombinant mammalian polypeptides and antibodies specific to mammalian islet cell antigen 1851 polypeptides are presented.
    Type: Application
    Filed: June 7, 2001
    Publication date: August 1, 2002
    Applicant: ZymoGenetics, Inc.
    Inventors: Wayne Kindsvogel, Laura J. Jelinek, Paul O. Sheppard, William A. Hagopian, James M. LaGasse
  • Islet cell antigen 1851
    Patent number: 6300093
    Abstract: A mammalian islet cell antigen polypeptide involved in the development of insulin-dependent diabetes mellitus (IDDM) is disclosed. This islet cell antigen polypeptide, 1851, was found to contain regions of homology to the protein tyrosine phosphatase family. Methods for diagnosis and treatment, including use in immunoprecipitation assays and the induction of immune tolerance using the recombinant mammalian polypeptides and antibodies specific to mammalian islet cell antigen 1851 polypeptides are presented.
    Type: Grant
    Filed: March 5, 1997
    Date of Patent: October 9, 2001
    Assignees: ZymoGenetics, Inc., University of Washington
    Inventors: Wayne Kindsvogel, Laura J. Jelinek, Paul O. Sheppard, William A. Hagopian, James M. LaGasse
  • Nuclear receptor polypeptide ZPPAR4
    Patent number: 6262234
    Abstract: The present invention relates to ZPPAR4 polynucleotide molecules and ZPPAR4 polypeptide molecules. ZPPAR4 is a novel member of the nuclear receptor superfamily. The novel ZPPAR4 nuclear receptor can be used to examine ZPPAR4-related complex transcriptional networks and biological processes. The disclosed ZPPAR4 polynucleotides and polypeptides provide a means to identify the natural ligand for ZPPAR4, as well as agonists and antagonists thereof.
    Type: Grant
    Filed: June 26, 1998
    Date of Patent: July 17, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: James L. Holloway, Laura J. Jelinek, Diane M. Durnam, Hal Blumberg
  • Method of detecting glucagon receptor antagonists
    Patent number: 5919635
    Abstract: The present invention provides isolated DNA molecules comprising a DNA segment encoding a glucagon receptor. Also provided are DNA constructs comprising a first DNA segment encoding a glucagon receptor operably linked to additional DNA segments required for the expression of the first DNA segment, as well as host cells containing such DNA constructs.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: July 6, 1999
    Assignee: ZymoGenetics, Inc.
    Inventors: Wayne R. Kindsvogel, Laura J. Jelinek, Paul O. Sheppard, Francis J. Grant, Joseph L. Kuijper, Donald C. Foster, Si Lok, Patrick J. O'Hara
  • Recombinant production of glucagon receptors
    Patent number: 5776725
    Abstract: The present invention provides isolated DNA molecules comprising a DNA segment encoding a glucagon receptor. Also provided are DNA constructs comprising a first DNA segment encoding a glucagon receptor operably linked to additional DNA segments required for the expression of the first DNA segment, as well as host cells containing such DNA constructs.
    Type: Grant
    Filed: July 1, 1993
    Date of Patent: July 7, 1998
    Assignee: ZymoGenetics, Inc.
    Inventors: Wayne R. Kindsvogel, Laura J. Jelinek, Paul O. Sheppard, Francis J. Grant, Joseph L. Kuijper, Donald C. Foster, Si Lok, Patrick J. O'Hara
  • Glucagon receptor proteins, peptides, and antibodies
    Patent number: 5770445
    Abstract: The present invention provides isolated DNA molecules comprising a DNA segment encoding a glucagon receptor. Also provided are DNA constructs comprising a first DNA segment encoding a glucagon receptor operably linked to additional DNA segments required for the expression of the first DNA segment, as well as host cells containing such DNA constructs.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: June 23, 1998
    Assignee: ZymoGenetics, Inc.
    Inventors: Wayne R. Kindsvogel, Laura J. Jelinek, Paul O. Sheppard, Francis J. Grant, Joseph L. Kuijper, Donald C. Foster, Si Lok, Patrick J. O'Hara